Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.69 |
| ▸ | CA1 | P00915 | 4/20 | 0.69 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.46 |
| ▸ | BIRC2 | Q13490 | 5/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6860859 | 1.00 | CA2 (0.69) | CA2CA1ZDHHC7BIRC2MAPK1 | |
| SCHEMBL6867848 | 0.94 | CA2 (0.61) | CA2CA1ZDHHC7BIRC2USP2 | |
| SCHEMBL6870979 | 0.93 | CA2 (0.59) | CA2CA1ZDHHC7BIRC2USP2 | |
| SCHEMBL205652 | 0.93 | CA2 (0.59) | CA2CA1ZDHHC7BIRC2USP2 | |
| SCHEMBL6873801 | 0.93 | CA2 (0.59) | CA2CA1ZDHHC7BIRC2USP2 | |
| SCHEMBL6870714 | 0.93 | CA2 (0.59) | CA2CA1ZDHHC7BIRC2USP2 | |
| SCHEMBL6870778 | 0.93 | CA2 (0.59) | CA2CA1ZDHHC7BIRC2USP2 | |
| SCHEMBL6873130 | 0.93 | CA2 (0.59) | CA2CA1ZDHHC7BIRC2USP2 | |
| SCHEMBL6863926 | 0.93 | CA2 (0.59) | CA2CA1ZDHHC7BIRC2USP2 | |
| SCHEMBL6868274 | 0.93 | CA2 (0.59) | CA2CA1ZDHHC7BIRC2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418030-B1 | CURING AGENT COMPOSITION | KAO CORP (JP) | 2019-09-25 | — | — | EP | claimed |
| US-20120043694-A1 | CURING AGENT COMPOSITION | KAO CORPORATION (JP) | 2012-02-23 | — | — | US | claimed |
| EP-2418030-A1 | CURING AGENT COMPOSITION | Kao Corporation (JP) | 2012-02-15 | — | — | EP | claimed |
| CN-113336709-A | Preparation method of N, N-dimethylacetamide | 上海立科化学科技有限公司 | 2021-09-03 | — | — | CN | disclosed |
| EP-2418030-B1 | CURING AGENT COMPOSITION | KAO CORP (JP) | 2019-09-25 | — | — | EP | disclosed |
| CN-107207515-B | Pyrazine compounds for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2019-05-28 | — | — | CN | disclosed |
| EP-2581148-B1 | PROCESS FOR PRODUCTION OF MOLDS | KAO CORP (JP) | 2018-10-24 | — | — | EP | disclosed |
| CN-107207515-A | Pyrazine compounds for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2017-09-26 | — | — | CN | disclosed |
| US-8729152-B2 | Curing agent composition | KAO CORPORATION (JP) | 2014-05-20 | — | — | US | disclosed |
| EP-2581148-A1 | PROCESS FOR PRODUCTION OF MOLDS | Kao Corporation (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-20120261087-A1 | PROCESS FOR PRODUCING A MOLD | KAO CORPORTATION (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20120043694-A1 | CURING AGENT COMPOSITION | KAO CORPORATION (JP) | 2012-02-23 | — | — | US | disclosed |
| EP-2418030-A1 | CURING AGENT COMPOSITION | Kao Corporation (JP) | 2012-02-15 | — | — | EP | disclosed |
| EP-1165633-B1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE SPA (IT) | 2004-07-14 | — | — | EP | disclosed |
| US-6716939-B2 | COMPRISING TITANIUM, MAGNESIUM, HALOGEN AND AN ELECTRON DONOR COMPOUND SELECTED FROM ESTERS OF SUBSTITUTED SUCCINIC ACIDS | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2004-04-06 | — | — | US | disclosed |
| US-20020183575-A1 | Components and catalysts for the polymerization of olefins | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120043694-A1 | CURING AGENT COMPOSITION | ERG28, SMARCA5, MYB | CA2 3521/4885CA1 2337/4885ZDHHC7 1130/4885 |
| US-20020183575-A1 | Components and catalysts for the polymerization of olefins | SCO2, ECI1, MT-CO2 | CA2 1406/4885CA1 1593/4885ZDHHC7 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.